Brilliant Violet 510™ anti-human CD3 Antibody

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.⁴ The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
4. Li B, et al. 2005. Immunology 116:487.
5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed

Product Citations

1. Swadling L, et al. 2022. Nature. 601:110. PubMed
2. Bjarnadóttir U, et al. 2022. Scand J Immunol. 95:e13116. PubMed
3. Rowntree LC, et al. 2022. Immunity. 55:1299. PubMed
4. McEvoy CM, et al. 2022. Nat Commun. 13:7634. PubMed
5. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
6. Touizer E, et al. 2023. iScience. 26:105862. PubMed
7. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
8. Wheatley A, et al. 2016. Sci Rep. 6: 26478. PubMed
9. Nguyen THO, et al. 2023. Cell Rep Med. 4:101017. PubMed
10. Zhang W, et al. 2023. Nat Immunol. 24:966. PubMed
11. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
12. Lamichhane R, et al. 2020. Eur J Immunol. 50:178. PubMed
13. Leeansyah E, et al. 2015. PLoS Pathog. 11: 1005072. PubMed
14. Ishizaka A, et al. 2016. J Virol. 90: 5665 - 5676. PubMed
15. Andrews SF et al. 2019. Immunity. 51(2):398-410 . PubMed
16. Kimura I, et al. 2022. Cell Rep. 38:110218. PubMed
17. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
18. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
19. Chiu Y, et al. 2016. Sci Rep. 6:19227. PubMed
20. Abreu C, et al. 2014. PLoS One. 9:97257. PubMed
21. Piepenbrink MS, et al. 2021. Cell Reports Medicine. 2(3):100218. PubMed
22. Sutton HJ, et al. 2021. Cell Reports. 34(6):108684. PubMed
23. Zhou J, et al. 2015. J Immunol. 194:4688. PubMed
24. Petrelli A, et al. 2018. J Clin Invest. 128:4669. PubMed
25. Antonucci L, et al. 2020. Journal of Immunology Research. 3257.929861. PubMed
26. Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed
27. Juno JA, et al. 2020. Nat Med. 26:1428. PubMed
28. Kreutmair S, et al. 2021. Immunity. . PubMed
29. Tan J, et al. 2021. Sci Transl Med. 13: . PubMed
30. Nguyen THO, et al. 2021. Immunity. 54:1066. PubMed
31. Yu C, et al. 2021. Med (N Y). 2:755. PubMed
32. Lu Q, et al. 2021. Immunity. 54(6):1304-1319.e9. PubMed
33. Ehlers L, et al. 2021. The FASEB Journal. 35(7):e21684. PubMed
34. Sordé L, et al. 2017. Immunity, Inflammation, and Disease. 10.1002/iid3.167. PubMed
35. van den Hoogen P, et al. 2020. PLoS One. 14:e0227283. PubMed
36. Port JR, et al. 2020. J Virol. 94:. PubMed
37. Lozano-Rodríguez R, et al. 2022. Cell Rep. 38:110235. PubMed
38. Einkauf KB, et al. 2019. J Clin Invest. 129:988. PubMed
39. Einkauf KB, et al. 2022. Cell. 185:266. PubMed
40. Jiang C, et al. 2020. Nature. 261:585. PubMed
41. Wang L, et al. 2021. Science. 373:. PubMed
42. Dacon C, et al. 2022. Cell Host Microbe. Online ahead of print. PubMed
43. Motozono C, et al. 2021. Cell Host Microbe. . PubMed
44. Gross C, et al. 2016. Proc Natl Acad Sci U S A. 113: 2973 - 2982. PubMed
45. Cho H, et al. 2021. Sci Transl Med. 13:eabj5413. PubMed
46. Smalley M, et al. 2020. iScience. 23:101229. PubMed
47. Hearps AC, et al. 2017. Front Immunol. 0.840972222. PubMed
48. Cui J, et al. 2019. Neuro Oncol. 21:1436. PubMed
49. Abd Hamid M et al. 2019. Cancer Immunol Res. 7(8):1293-1306 . PubMed
50. Seydoux E, et al. 2020. Immunity. 53:98. PubMed
51. Sant S, et al. 2020. PLoS Pathog. 16:e1008714. PubMed
52. Burian A, et al. 2016. PLoS One. 11: 0163297. PubMed
53. Aguilar–Briseñ o JA, et al. 2020. Nat Commun. 2.664583333. PubMed
54. Lamichhane R et al. 2019. Cell Rep. 28(12):3061-3076 . PubMed

RRID

AB_2561376 (BioLegend Cat. No. 317331)
AB_2561376 (BioLegend Cat. No. 317332)

Antigen Details

Structure

Ig superfamily, the subunits CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) form the CD3/TCR complex, 20 kD

Distribution

Mature T and NK T cells, thymocyte differentiation

Function

Antigen recognition, signal transduction, T cell activation

Ligand/Receptor

Peptide antigen bound to MHC

Cell Type

NKT cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
3. Lanier L, et al. 1986. J. Immunol. 137:2501.

Gene ID

916 View all products for this Gene ID

UniProt

View information about CD3 on UniProt.org

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Other Formats